A new review article published in Nature Reviews Cancer on May 20, 2026, emphasizes the critical role of DNA methylation heterogeneity in shaping the tumor microenvironment. The study, led by researchers at the University of Cambridge, highlights how variability in DNA methylation patterns influences cancer progression and response to treatment.
DNA methylation, a key epigenetic modification, regulates gene expression without altering the DNA sequence. The review synthesizes findings from over 200 studies, showing that methylation heterogeneity within tumors can create diverse cellular states, affecting immune evasion and drug resistance. According to Dr. Sarah Thompson, lead author, 'Understanding this variability is essential for developing more precise treatment strategies that target specific tumor subtypes.'
The research underscores that tumors with high methylation heterogeneity are often more aggressive and less responsive to standard therapies. The authors propose that integrating methylation profiling into clinical practice could help identify patients who might benefit from immunotherapy or epigenetic drugs. The review was funded by Cancer Research UK and the National Institutes of Health.
